RE: News in the Coming Yeargood post...
When you map it all out like that , it really looks compelling. It will be nice when the company can attach a reasonable and reliable baseline financial model to this. Until then, we can only speculate the true intrinsic value.
The fact is, today's share price is still completely disconnected from any educated (even ultra conservative ) estimates of the underlying intrinsic value here.... and there's virtually no speculative value component either.
Any combination of positive 1402 results, or increased media, market and industry attention surrounding the EU accredation of the PRDT / MacoPharma bloodbag or the related bloodbag product launch is the kind of BIG catalyst that will change all of that.
Whats going to happen when the market understands that PROMETIC / ARC is the only company to have an ACCREDITED device to remove BSE / CJB prions from blood and its for sale !? Do you think that'll make the international news and papers ? I guess that's what it'll take for the market to understand....
Dont you think reasonably that if Prometic is able to remove and detect infected prions from blood that they are fundamentally able to test human and animal BLOOD for infectivity ? Do you think anyone might be interested in that ?? ..... apparently the market doesnt care
If that's not enough, what about the PBI1402 news release in JULY that was largely ignored by the market ? The company comes out and says that the compound STIMULATES Red and White Blood cell growth in HUMAN BONE marrow in-vitro. In its subsequent marketing pc's it goes on to show how PBI-1402 had a larger in-Vitro effect than h-EPO and close to triple h-EPO's effect when dosed with h-EPO... I believe that h-EPO is one of AMGEN's single biggest drugs.
From what I understand, the market for in-VITRO application alone for these drugs is close to a BILLION dollars. Doctors will remove human marrow prior to chemotherapy, stimulate the marrow in-Vitro and then administer it back to the patient for post chemo anemia. This apparently represents 8-10% of h_EPO sales.
READ: doesnt that mean that PBI-1402 (if proven safe in this phase one trial ) already has in-Vitro efficacy for approximately a Billion dollar indication ? Do you think that might interest any drug companies ? ... apparently the market doesnt care
What if PBI-1402 has similar indications to h-EPO in healthy humans ?
.... apparently the market doesnt care.
fun stuff...